Clinical Trial Detail

NCT ID NCT01769547
Title A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ontario Clinical Oncology Group (OCOG)|Novartis Pharmaceuticals
Indications

malignant pleural mesothelioma

Therapies

Dovitinib

Age Groups: adult

No variant requirements are available.